American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 642-644 , October 2008

Normalization of Hemoglobin in Patients With CKD May Cause Harm: But What Is the Mechanism?

  • T.J. Littlewood, MBBCh, FRCP, FRCPath, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to T.J. Littlewood, MBBCh, FRCP, FRCPath, MD, Department of Haematology, Oxford Radcliffe NHS Trust, Oxford OX3 9DU, UK

References 

  1. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727–736
  2. Winearls C, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175–1178
  3. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573–578
  4. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter trial). Ann Intern Med. 1989;111:992–1000
  5. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  6. Drueke TB, Locatelli F, Clyne N, et al. Normalisation of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  7. Singh AK, Szczech L, Tang KL, et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  8. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381–388
  9. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  10. Hedenus M, Adriansson M, SanMiguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394–403
  11. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  12. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960–5972
  13. Nowrousian MR, Dunst J, Vaupel P. Erythropoiesis-stimulating agents: Favourable safety profile when used as indicated. Stralenther Onkol. 2008;3:121–136
  14. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in haemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  15. Tobu M, Iqbal O, Fareed D, et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost. 2004;10:225–232
  16. Tang WW, Stead RA, Goodkin DA. Effects of epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol. 1998;18:262–273
  17. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14–31
  18. Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ. Association of pre-treatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007;43:283–288
  19. Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175:859–863
  20. Henry DH, Dahl NV, Auerbach M. Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis?. Blood (ASH Annual Meeting Abstracts). 2007;1625;(abstr)
  21. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Beckie M, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–3080
  22. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–379
  23. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimises the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307
  24. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–242
  25. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron With Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984

PII: S0272-6386(08)01100-1

doi: 10.1053/j.ajkd.2008.07.001

American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 642-644 , October 2008

Article Tools